A functional Notch–survivin gene signature in basal breast cancer by Lee, Connie W et al.
Open Access
Available online http://breast-cancer-research.com/content/10/6/R97
Page 1 of 12
(page number not for citation purposes)
Vol 10 No 6 Research article
A functional Notch–survivin gene signature in basal breast cancer
Connie W Lee1, Karl Simin1, Qin Liu2, Janet Plescia1, Minakshi Guha1, Ashraf Khan3, Chung-
Cheng Hsieh1 and Dario C Altieri1
1Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, 
USA
2Department of Medicine, Preventive and Behavioral Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 
01605, USA
3Department of Pathology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA
Corresponding author: Dario C Altieri, dario.altieri@umassmed.edu
Received: 21 Jul 2008 Revisions requested: 27 Aug 2008 Revisions received: 12 Nov 2008 Accepted: 24 Nov 2008 Published: 24 Nov 2008
Breast Cancer Research 2008, 10:R97 (doi:10.1186/bcr2200)
This article is online at: http://breast-cancer-research.com/content/10/6/R97
© 2008 Lee et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Basal-type, or triple-negative, breast cancer
(lacking estrogen receptor, progesterone receptor, and human
epidermal growth factor receptor-2 expression) is a high-risk
disease for which no molecular therapies are currently available.
We studied genetic signatures of basal breast cancer
potentially suitable for therapeutic intervention.
Methods We analyzed protein expression of the Notch-1
intracellular domain and survivin by immunohistochemistry in a
series of basal breast cancer patients. A hierarchical clustering
and overall survival analysis was carried out on a microarray
mRNA database of 232 breast cancer patients. Fifteen
published mRNA datasets containing estrogen receptor-
negative or estrogen receptor-positive samples were subjected
to meta-analysis for co-segregated gene expression.
Experiments of plasmid transfection and gene silencing were
carried out in estrogen receptor-negative MDA-MB-231 breast
cancer cells.
Results The developmental signaling regulator Notch-1 was
highly expressed in breast cancer, compared with normal tissue,
and was segregated with basal disease. Higher Notch-1 levels
correlated with progressively abbreviated overall survival, and
with increased expression of survivin, a tumor-associated cell
death and mitotic regulator implicated in stem cell viability.
Analysis of Pearson's correlation coefficient indicated that
Notch-1  and  survivin  co-segregated in basal breast cancer.
Notch-1 stimulation in MDA-MB-231 cells increased survivin
expression, whereas silencing Notch reduced survivin levels.
Conclusions A Notch-1–survivin functional gene signature is a
hallmark of basal breast cancer, and may contribute to disease
pathogenesis. Antagonists of Notch and survivin currently in the
clinic may be tested as novel molecular therapy for these
recurrence-prone patients.
Introduction
The introduction of molecular gene signatures in breast cancer
provides important prognostic and predictive information [1-
3], and holds promise for individualized molecular therapy of
these patients [4]. Certain subtypes of breast cancer, how-
ever, continue to pose therapeutic challenges [4]. For exam-
ple, basal breast cancer is a myoepithelial disease variant
characterized by high histologic grade [5], by the absence of
HER-2 (ErB2) and receptors for estrogen and progesterone
[6], by the expression of basal cytokeratins (that is, keratin 5)
and proliferation-associated genes [7,8], as well as by defects
in genomic gatekeepers, p53, or BRCA1 [9]. While immuno-
histochemical diagnosis of basal breast cancer is straightfor-
ward [6], these patients have limited therapeutic options: the
response to mainstay chemotherapy is not uniform and is
affected by the type of drugs used [10]; estrogen or HER-2
targeting is not indicated; and attempts to disable ancillary sig-
naling pathways, for instance coordinated by the epidermal
growth factor receptor, have so far shown little promise [11].
This adds to a high rate of relapses, which in several series has
been linked to shortened overall survival and to death from dis-
ease [12].
ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; NIC: Notch-1 intracellular domain; PBS: phosphate-buffered saline; 
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Although the cell of origin of basal breast cancer has not been
conclusively identified [5], a link to the progenitor/stem cell
compartment of the mammary epithelium has been proposed
[13]. In this context, developmental gene expression pathways
that control the interplay between cell proliferation, survival,
and differentiation are candidates for stem cell-derived mam-
mary tumorigenesis [14]. One such pathway is centered on
the Notch family of cell surface receptors [15] – which affects
the mammary stem cell niche [16], and has been associated
with malignant transformation [17] and aggressive tumor
behavior [18]. Notch expression is correlated to human breast
cancer formation but the downstream pathways that guide
such behavior are still under investigation [19,20].
Among the candidate effector molecules controlling stem cell
viability is survivin, a dual regulator of cell division and apopto-
sis, broadly overexpressed in cancer [21]. Consistent with its
onco-fetal pattern of expression, survivin is essential for tissue
homeostasis [21] – and conditional knockout studies have
suggested a potential critical role of this pathway in maintain-
ing stem cell viability, at least in certain tissue compartments
[22].
In the present study, we used a combination of hierarchical
clustering and overall survival analysis of a novel microarray
dataset, meta-analysis of published gene profiling studies, and
cell culture experiments to investigate a potential role of a
Notch-1–survivin signaling axis in breast cancer.
Materials and methods
Immunohistochemistry
Nine cases of basal breast cancers with associated clinical
and pathological data were obtained from the archives of the
Department of Pathology, University of Massachusetts Medi-
cal School. Analysis of anonymous discarded tissue with no
patient identifiers was approved by and in compliance with
Institutional Review Board guidelines.
Tissue sections (5 μm) were cut from paraffin blocks, depar-
affinized in xylene, rehydrated, and baked overnight at 60°C.
Slides were quenched for endogenous peroxidase with 3%
H2O2 in methanol for 20 minutes, and were processed for anti-
gen retrieval by pressure cooking in 9 mM sodium citrate, pH
6.0, for 20 minutes. Slides were washed in PBS, and incu-
bated overnight at 4°C with a rabbit antibody to the Notch-1
intracellular domain (NIC) or control IgG, were rinsed, and
were further incubated with a biotinylated anti-rabbit IgG for
10 minutes at 22°C. After addition of streptavidin-conjugated
horseradish peroxidase, the slides were incubated with 3',3'-
diamino-benzidine for 3 to 10 minutes, and were counter-
stained with hematoxylin, as described previously [23].
Hierarchical clustering analysis of Notch-1 mRNA 
expression in breast cancer
The log2 Cy5/Cy3 ratios of 232 cases of human breast cancer
and their associated clinical data were downloaded from the
University of North Carolina Microarray Database [24,25].
Only genes where the Lowess normalized intensity values in
both channels were > 30 and data existed in > 70% samples
were included for analysis. The gene set was further filtered to
include only genes with Pearson's correlation coefficient >
0.58 with Notch-1 (n = 101).
Two-way hierarchical clustering was performed using Cluster
v3 [26], and the results were displayed using JavaTreeview
[27]. Analysis of overall survival (log-rank test) was carried out
using JMP 6.0 [28] (SAS Institute, Cary, NC, USA) on the sub-
set of breast cancer patients in this cohort with available clini-
cal data (n = 125). Data were plotted for each quartile of
normalized Notch-1 log2 ratios, from highest (first quartile) to
lowest (fourth quartile). The breast cancer patients were fur-
ther divided into basal (n = 35) or nonbasal (n = 88) sub-
groups and were analyzed for overall survival (log-rank test)
using JMP 6.0 [28].
Meta-analysis of Oncomine microarray data
We reviewed Oncomine [29,30] for independent human
breast cancer microarray datasets comparing estrogen recep-
tor (ER)-negative and ER-positive tumors. Databases from 15
studies were found to contain Notch-1 and survivin relative
expression data. The patient characteristics and analyses per-
formed in each study are summarized in Table 1. Descriptive
statistics including the mean, standard error, and a two-tailed
unpaired t test were calculated for the comparisons between
ER-positive and ER-negative samples within each study. Sep-
arately for ER-negative and ER-positive samples, a Pearson's
correlation coefficient (r) was calculated for each study to
measure levels of pair-wise co-expression between Notch-1,
survivin, and keratin-5.
The 95% confidence interval for r was calculated based on
Fisher's Z transformation [31]. In one study a Fisher's Z trans-
formation could not be performed for ER-negative samples (n
= 3) [32], and an approximate variance for a Pearson's corre-
lation coefficient was used to derive its 95% confidence inter-
val. To summarize ER-specific results from the individual
studies, Fisher's Z transformation and its variance were used
in pooling correlation from different studies. The weighted
average of Fisher's Z transformation and its 95% confidence
interval were first estimated based on a fixed-effect model, tak-
ing into account the variance associated with each study. The
ER-specific pooled estimate of Pearson's correlation coeffi-
cient and its 95% confidence interval were then derived from
the estimates based on the Fisher's Z  transformation. We
applied a random-effect model for meta-analysis [33] to evalu-
ate whether levels of co-expressions between Notch-1, sur-Available online http://breast-cancer-research.com/content/10/6/R97
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Table 1
Published datasets included in the meta-analysis
Study n Median age 
(years)
Microarray Tumor size Lymph nodes 
(LN)
Treatment Stage/grade
Chin and 
colleagues 
[55]
118 55.3 
(SD = 14.3)
Affymetrix 2.6 cm 
(SD = 1.3)
67 LN-positive, 
51 LN-negative
60% tamoxifen, 
52% adjuvant 
chemotherapy, 
51% radiation
26 stage 1, 70 
stage 2, 14 
stage 3, 5 stage 
4; 10 grade 1, 
42 grade 2, 61 
grade 3; 5 
unknown
Desmedt and 
colleagues 
[56]
198 47 (all < 61) Affymetrix < 5 cm Node-negative T1–T2
Ginestier and 
colleagues 
[57]
55 Affymetrix 19 amplified for 
20q13, 36 
unamplified for 
20q13
Consecutive 
cases, unilateral 
localized 
invasive breast 
cancer
Hess and 
colleagues 
[58]
133 Training set, 52 
(range 29 to 
79); validation 
set, 50 
(range 28 to 
73)
Affymetrix Preoperative 
weekly paclitaxel 
and fluorouracil–
doxorubicin–
cyclophosphami
de 
chemotherapy
Stage I, stage II, 
stage III
Ivshina and 
colleagues 
[59]
249 
(Uppsala 
cohort)
62.3 Affymetrix 2.9 cm 35% node-
positive
30.3% 
endocrine 
therapy, 10.7% 
chemotherapy, 
1.7% 
combination 
therapy, 58.8% 
no systemic 
therapy
68 grade 1, 126 
grade 2, 55 
grade 3
Miller and 
colleagues 
[60]
251 62.1 
(SD = 13.9)
Affymetrix 22.4 mm 
(SD = 12.5)
84/253 LN 
metastasis, 160 
node-negative, 9 
unknown node 
status
143 no adjuvant 
therapy; others 
with systemic 
adjuvant 
therapy, and/or 
chemotherapy
Minn and 
colleagues 
[61]
82 55.8 
(SD = 13.5)
Affymetrix 3.68 cm 
(SD = 1.77 
cm)
Average 3.5 (SD 
= 5.98) axillary 
LN
Adjuvant 
chemotherapy 
and/or hormonal 
therapy
Richardson 
and colleagues 
[62]
39 Affymetrix
Saal and 
colleagues 
[37]
105 61 
(range 26 to 
77)
Non-Affymetrix 27 mm 
(range 2 to 50 
mm)
65 (62%) LN-
positive
Treated 
uniformly with 2 
years of adjuvant 
tamoxifen
Stage II, primary 
breast cancer
Sotiriou and 
colleagues 
[63]
119 
(KJ125 dataset)
45% < 50, 
55% > 50
Affymetrix 61% < 2 cm, 
39% > 2 cm
LN-negative No adjuvant 
systemic therapy
34 grade 1, 46 
grade 2, 28 
grade 3, 17 not 
available
Turashvili and 
colleagues 
[32]
10 Affymetrix 3 grade I, 5 
grade II, 2 grade 
III
van de Vijver 
and colleagues 
[64]
295 < 52 Non-Affymetrix < 5 cm 151 LN-
negative, 144 
LN-positive
Modified radical 
mastectomy or 
breast-
conserving 
surgery
Stage I or stage 
II breast cancer
Wang and 
colleagues 
[65]
286 54 (SD = 12) Affymetrix LN-negative No adjuvant 
treatmentBreast Cancer Research    Vol 10 No 6    Lee et al.
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vivin, and keratin-5  differ between ER-negative and ER-
positive samples among the different studies.
Cells, reagents and transfections
The breast adenocarcinoma MDA-MB-231 cell line was
obtained from the American Type Culture Collection (Manas-
sas, VA, USA), and was maintained in culture as recom-
mended by the supplier. The cDNA encoding activated NIC
was characterized previously [34]. MDA-MB-231 cells were
transfected with control plasmid cDNA or NIC cDNA (2 μg)
using 6 μl LipofectAmine (Invitrogen, Carlsbad, CA, USA) in
Opti-Mem medium (1 ml) (Gibco, Carlsbad, CA, USA). The
media was changed after 5 hours, and cells were harvested
after 24 hours.
The peptidyl γ-secretase inhibitor z-Leu-Leu-Nle-CHO was
purchased from Calbiochem (San Diego, CA, USA), and has
been characterized previously [35]. For gene silencing experi-
ments by siRNA, MDA-MB-231 cells were transfected with
double-stranded RNA oligonucleotide directed to Notch-1
(pool of three siRNA; Santa Cruz, Santa Cruz, CA, USA), sur-
vivin, or control nontargeted sequences using 10 μl HiPerfect
(Gibco). Cells under the various conditions were harvested
after 48 hours, and were analyzed by western blotting.
Results
Expression of Notch-1 and survivin in basal breast 
cancer
Recent studies have shown that Notch activation results in
increased expression of survivin in basal breast cancer cell
lines [35]. To determine whether a similar association occurs
in vivo, we examined by immunohistochemistry a panel of
basal breast cancer cases for expression of activated Notch-1
(NIC) and survivin. The average age of the nine patients was
52.3 ± 6.1 years. All cases were grade 3 tumors with negative
protein expression of ER, progesterone receptor, and HER-2,
and positive protein expression of keratin 5/6, as assessed by
immunohistochemistry. Activated Notch-1 was abundantly
expressed in all cases examined of basal breast cancer, and
was localized to both the cytosol and nuclei of tumor cells (Fig-
ure 1). Survivin was also strongly expressed in all basal breast
cancer cases, and was similarly localized to the nuclei and
cytosol of the tumor cell population (Figure 1).
Yu and 
colleagues 
[38]
96 (only 68 with 
Notch-1 and 
survivin data)
55 (SD = 10.9) Affymetrix 37.7 mm 
(SD = 17.9)
37.5% LN-
negative
2 unknown 
grade, 5 grade I, 
26 grade II, 63 
grade III
Zhao and 
colleagues 
[36]
59 (35 
intraductal 
carcinoma, 17 
intralobular 
carcinoma; 
three from each 
with unknown 
ER status)
Ductal, 53 (SD 
= 15.5); lobular, 
63.5 
(SD = 14.0)
Non-Affymetrix Ductal, 16 LN-
positive, 16 LN-
negative, 3 LN 
unknown; 
lobular, 7 LN-
positive, 7 LN-
negative, 4 LN 
unknown
Ductal, 5 grade 
I, 19 grade II, 11 
grade III; lobular, 
17 grade II, 1 
grade I
Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study 
criteria.
Table 1 (Continued)
Published datasets included in the meta-analysis
Figure 1
Expression of activated Notch-1 and survivin in basal breast cancer Expression of activated Notch-1 and survivin in basal breast cancer. Representative basal breast cancer cases were analyzed by immunohistochem-
istry. NIC, Notch-1 intracellular domain.Available online http://breast-cancer-research.com/content/10/6/R97
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Expression of Notch-1 mRNA in breast cancer microarray 
databases
We next analyzed the expression of Notch-1 mRNA in an
established breast cancer patient cohort. Supervised hierar-
chical clustering of 232 cases of human breast cancer [25],
using intrinsic gene analysis, revealed that higher expression
of Notch-1 segregated with basal breast cancer. Other known
markers of the disease, including keratin-5, keratin-14, and kit,
were also highly correlated with Notch-1 expression (r ≥ 0.58)
in this cohort (Figure 2).
One hundred and twenty-five patients with associated clinical
outcome data were further analyzed. When stratified accord-
ing to levels of Notch-1 log2 transcript ratios, tumors with the
highest quartile of Notch-1  gene expression (first quartile)
exhibited abbreviated overall survival with a median survival of
27 months compared with the other groups (P < 0.001 via the
log-rank test) (Figure 3a). Seventy-two percent of tumors in
this first quartile (23/32 tumors) were classified as basal
breast cancer, and the overall survival of these patients was
approximately 50% lower of that of the remaining population
(P < 0.02). Conversely, reduced levels of Notch-1 (second to
fourth quartiles) were associated with better overall survival
Figure 2
Notch-1 segregates with basal breast cancer Notch-1 segregates with basal breast cancer. Heat map of 232 cases of breast cancer. Unclassified, gray; normal breast-like, green; luminal A, light 
blue; luminal B, dark blue; HER-2+/estrogen receptor-negative (ER-), purple; basal, red.Breast Cancer Research    Vol 10 No 6    Lee et al.
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(Figure 3a). The percentage of basal breast cancers in these
groups was 17% (second quartile, 5/30 tumors), 20% (third
quartile, 6/30 tumors), and 10% (fourth quartile, 3/31 tumors),
respectively.
The tumors were then segregated based on basal or nonbasal
subgroup status and were analyzed for overall survival. In the
nonbasal breast tumors, the expression of Notch-1 was not
associated with significant differences in overall survival (P =
0.2734) (Figure 3b). In contrast, Notch-1 levels dictated over-
all survival in basal breast tumors (Figure 3c). In this basal sub-
group, increased Notch-1 expression (fourth quartile) greatly
reduced overall survival to the median of 26 months (Figure
3c). Comparatively, low levels of Notch-1 (first to third quar-
tiles) demonstrated improved overall survival (Figure 3c).
Gene expression correlation in basal breast cancer
We next carried out a meta-analysis of published microarray
datasets to identify genes associated with Notch and poten-
tially implicated in the molecular pathogenesis of basal breast
cancer. Based on our recent data [35], we focused on survivin
– a mitotic regulator and cell death inhibitor overexpressed in
breast cancer [3,21], and associated with unfavorable out-
come [2] – and keratin-5 – a marker of basal epithelium, often
linked to a progenitor/stem cell phenotype [13].
Fifteen microarray datasets, mostly employing Affymetrix tech-
nology, published between 2002 and 2007 met the search
criteria (Table 1). The overall median age of patients was 55.2
years. The breast tumors examined were typically < 5 cm,
encompassing all grades, and included lymph node-positive
and lymph node-negative disease. In one study, separate data-
bases for lobular and ductal breast cancer were examined [36]
– bringing the datasets analyzed to a total of 16. Two studies
did not contain downloadable keratin-5  expression data
[36,37], and one study contained 68 out of 96 samples with
Notch-1 and survivin data and 19 samples with keratin-5 data
[38]. Table 2 presents the descriptive statistics of each cohort
with respect to Notch-1,  survivin, and keratin-5  relative
expression.
A novel dual-gene signature in basal breast cancer
Analysis of 507 ER-negative and 1,356 ER-positive breast
cancer patients revealed that keratin-5 associated with ER-
negative breast cancers (Figure 4a) in seven out of 13 data-
sets, and that Notch-1 associated with ER-negative breast
cancers in nine out of 16 datasets (Table 2). Pooled estimates
of Pearson's correlation coefficient between Notch-1/keratin-
5 were 0.3315 and 0.2043 for ER-negative and ER-positive
breast cancers, respectively (P = 0.04) (Figure 4a). Similarly,
survivin and keratin-5 co-segregated in ER-negative breast
cancer, with a pooled estimate of Pearson's correlation coeffi-
cient of 0.1314 for ER-negative breast cancer and of -0.2408
for ER-positive breast cancer (P < 0.0001) (Figure 4b). A neg-
ative correlation exists between survivin and keratin-5 in ER-
positive breast cancers most probably because other tran-
scriptional and nontranscriptional mechanisms are likely to
control survivin expression in nonbasal cancers (Figure 4b).
Analysis of 604 ER-negative and 1,463 ER-positive breast
cancer patients revealed that survivin segregated with ER-
negative tumors (two-tailed P < 0.05) in 12 out of 16 cohorts
(Table 2). The Pearson's correlation coefficients between
Notch-1 and survivin were 0.1804 and -0.0674 for ER-nega-
tive and ER-positive breast cancers, respectively (P < 0.0001)
(Figure 4c).
Figure 3
Overall survival Overall survival. (a) Kaplan–Meier curves of differential overall survival 
were plotted according to Notch-1 expression in the entire cohort 
(quartiles). (b) Nonbasal tumors and (c) basal tumors were subgrouped 
into high Notch-1 expression (fourth quartile) or low Notch-1 expres-
sion (first to third quartiles) and were analyzed for overall survival.Available online http://breast-cancer-research.com/content/10/6/R97
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Table 2
Descriptive statistics of studies in the meta-analysis
Study Total n Subset Survivin Notch-1 Keratin 5
Mean SEM P Mean SEM P Mean SEM P
Chin and 
colleagues [55]
118 ER- 
(n = 43)
0.7723 0.0815 1.353 × 
10-5
0.7793 0.0548 2.231 × 
10-5
0.9844 0.1436 4.893 × 
10-6
ER+ 
(n = 75)
0.3371 0.0437 0.5027 0.0245 0.1884 0.0678
Desmedt and 
colleagues [56]
198 ER- 
(n = 64)
0.7238 0.0478 1.414 × 
10-8
0.3254 0.0389 3.951 × 
10-4
0.6649 0.0996 1.159 × 
10-2
ER+ 
(n = 134)
0.3278 0.0460 0.1658 0.0193 0.3773 0.0507
Ginestier and 
colleagues [57]
55 ER- 
(n = 28)
0.7621 0.1251 9.689 × 
10-5
1.4343 0.0504 2.933 × 
10-4
1.2587 0.2116 1.219 × 
10-2
ER+ 
(n = 27)
0.4959 0.0954 1.1536 0.0520 0.5842 0.1492
Hess and 
colleagues [58]
133 ER- 
(n = 51)
0.0776 0.0451 2.071 × 
10-3
0.2169 0.0454 1.203 × 
10-1
0.5110 0.1706 1.165 × 
10-4
ER+ 
(n = 82)
-0.0956 0.0309 0.1238 0.0384 -0.2216 0.0480
Ivshina and 
colleagues [59]
249a ER- 
(n = 34)
0.4877 0.0847 1.064e × 
10-7
0.3819 0.0589 1.643 × 
10-2
0.7071 0.1683 1.403 × 
10-1
ER+ 
(n = 211)
-0.0950 0.0408 0.2299 0.0137 0.4438 0.0479
Miller and 
colleagues [60]
251 ER- 
(n = 34)
0.3701 0.0681 2.780 × 
10-8
0.3011 0.0443 2.073 × 
10-2
0.4714 0.1310 2.638 × 
10-1
ER+ 
(n = 213)
-0.1337 0.0382 0.1905 0.0113 0.3165 0.0389
Minn and 
colleagues [61]
82 ER- 
(n = 42)
0.1969 0.0719 1.809 × 
10-4
0.4515 0.0529 7.897 × 
10-5
1.1060 0.1311 2.391 × 
10-6
ER+ 
(n = 57)
-0.1821 0.0652 0.2036 0.0247 0.2624 0.1028
Richardson and 
colleagues [62]
39 ER- 
(n = 24)
-0.1141 0.1363 6.374 × 
10-3
1.1360 0.0621 1.216 × 
10-1
1.1878 0.1436 4.670e × 
10-3
ER+ 
(n = 15)
-0.6187 0.1089 1.0139 0.0457 0.6193 0.1225
Saal and 
colleagues [37]
105 ER- 
(n = 60)
-1.3798 0.1075 5.143 × 
10-6
0.2043 0.0756 3.033 × 
10-3
ER+ 
(n = 45)
-2.1290 0.1121 -0.1145 0.0728Breast Cancer Research    Vol 10 No 6    Lee et al.
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Notch-1 regulation of survivin expression
Consistent with the model presented above, recent studies
have shown that survivin may function as a direct transcrip-
tional target of Notch-1, thus controlling mitotic transition and
resistance to apoptosis in breast cancer [35]. In agreement
with these data, transfection of ER-negative breast cancer
MDA-MB-231 cells with NIC resulted in increased survivin
expression, as determined by western blotting, whereas acute
siRNA silencing of Notch was associated with reduced sur-
vivin levels and induction of apoptosis (data not shown). Simi-
larly, inhibition of Notch signaling by a pharmacologic inhibitor
of γ-secretase suppressed survivin gene expression (data not
shown), validating the identity of survivin as a direct transcrip-
tional target of Notch in breast cancer cells [35].
Discussion
In the present study, we have shown that Notch-1 is preferen-
tially expressed in breast cancer, as compared with normal tis-
sues, segregates with basal disease, and correlates with
abbreviated survival. In a meta-analysis of multiple, independ-
ent microarray datasets, Notch-1,  survivin, and keratin-5
selectively co-associated with ER-negative versus ER-positive
breast cancer patients. Consistent with recent observations
[35], survivin was validated as a direct transcriptional target of
Notch in model ER-negative breast cancer cells.
Sotiriou and 
colleagues [63]
119 ER- 
(n = 34)
0.4834 0.0320 2.528 × 
10-3
0.2702 0.0565 1.323 × 
10-4
0.9849 0.1107 9.396 × 
10-3
ER+ 
(n = 85)
0.3691 0.0166 0.0181 0.0196 0.6560 0.0499
Turashvili [32] 10 ER- (n = 3) 0.1268 0.1688 2.533 × 
10-1
1.1991 0.1243 3.082 × 
10-1
0.6117 0.3735 6.750 × 
10-1
ER+ (n = 7) -0.2686 0.2733 1.0239 0.0709 0.3655 0.4358
van de Vijver 
and colleagues 
[64]
295 ER- 
(n = 69)
0.3719 0.2218 1.847 × 
10-12
0.6277 0.1148 1.418 × 
10-10
-0.7917 0.4073 1.748 × 
10-5
ER+ 
(n = 226)
-1.7301 0.1580 -0.2900 0.0590 -2.8083 0.1822
Wang and 
colleagues [65]
286 ER- 
(n = 77)
0.0902 0.0459 2.284 × 
10-8
0.4139 0.0282 2.255 × 
10-11
0.8906 0.0819 3.242 × 
10-7
ER+ 
(n = 209)
-0.2387 0.0318 0.1784 0.0151 0.3844 0.0459
Yu and 
colleagues [38]
68 (19) ER- 
(n = 15)
-0.2546 0.0874 1.689 × 
10-1
-0.2712 0.1090 1.946 × 
10-4
1.8394* 0.2312* 2.280 × 
10-2 *
ER+ (n = 4) -0.4225 0.0831 0.7625 0.0431 0.9196* 0.2431*
Zhao and 
colleagues 
(lobular) [36]
16 ER- (n = 4) -2.4418 0.2721 6.851 × 
10-1
0.0416 0.4079 7.011 × 
10-1
ER+ 
(n = 12)
-2.3108 0.1269 -0.1367 0.1083
Zhao and 
colleagues 
(ductal) [36]
34 ER- 
(n = 11)
-1.4613 0.2938 1.440 × 
10-1
0.3298 0.3722 1.769 × 
10-1
ER+ 
(n = 23)
-2.0013 0.1981 -0.2272 0.1104
Mean, standard error of mean (SEM), and P value between estrogen receptor-negative (ER-) and estrogen receptor-positive (ER+) breast cancers 
are presented for Notch-1, survivin, and keratin-5 expression in the analyzed datasets. aUppsala cohort. * Subset of samples with keratin-5 data.
Table 2 (Continued)
Descriptive statistics of studies in the meta-analysisAvailable online http://breast-cancer-research.com/content/10/6/R97
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These findings add to an in-depth molecular classification of
breast cancer [4] – and in particular basal breast cancer, a dis-
ease variant that still poses significant therapeutic challenges.
In addition to high-risk genetics [7,8] and aggressive histo-
logic features [5], it has been speculated that basal breast
cancer may originate from a progenitor/stem cell compartment
in the basal mammary epithelium. This is consistent with a pro-
posed role for Notch in mammary progenitor cell differentiation
and maintenance [39], and potentially in the early events of
their transformation [40]. Such a pathway may not be exclu-
Figure 4
Co-segregation of Notch-1, survivin, and keratin-5 in breast cancer Co-segregation of Notch-1, survivin, and keratin-5 in breast cancer. Pearson's correlation coefficient and the 95% confidence interval were calcu-
lated from the analysis of individual datasets. (a) Notch-1/keratin-5. (b) Survivin/keratin-5. (c) Notch-1/survivin. For study details, see Table 2. ER, 
estrogen receptor.Breast Cancer Research    Vol 10 No 6    Lee et al.
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sively limited to breast cancer [20], given that deregulated
Notch signaling has been implicated as a driver of disparate
malignancies [15], as promoting aberrant cell cycle progres-
sion [41], and associated with unfavorable outcome [18].
In this context, survivin appears ideally suited to function as a
pleiotropic, direct Notch effector gene in clinically aggressive
breast cancer [2]. At the molecular level, this involves occu-
pancy of discrete RPB-Jκ binding element(s) in the survivin
promoter upon Notch activation, which results in transcrip-
tional upregulation of survivin levels, inhibition of apoptosis,
and acceleration of mitotic transitions selectively in ER-nega-
tive breast cancer cells [35]. Whether deregulation of a
Notch–survivin signaling axis is preferentially operative in a
progenitor/stem cell compartment is currently not known.
Intriguing, however, is that another developmental gene
expression pathway (that is, Wnt/β-catenin) has been impli-
cated in controlling survivin levels in intestinal crypt progenitor
cells, potentially contributing to colon cancer [42], and that
survivin expression been consistently associated with stem-
ness gene signatures of mesenchymal [43], neuronal [44], and
skin [45] progenitor cells. Results of conditional knockout
studies appear to support this model, as heterozygous dele-
tion of survivin produced complete bone marrow ablation, loss
of hematopoietic progenitor/stem cells, and rapid animal mor-
tality [22]. This pathway may have a clear link to human dis-
ease, as lineage-specific methylation and silencing of the
survivin gene has been linked to bone marrow depletion in
myelodsyplastic syndrome [46]. With respect to breast can-
cer, Notch-dependent upregulation of survivin [35] may
broadly suppress apoptosis, deregulate cell cycle progression
[21], and ultimately promote resistance to mainstay therapeu-
tic agents in this disease, such as taxanes [47] and DNA dam-
aging agents [48].
Although the diagnosis of triple-negative, basal breast cancer
is straightforward [6], these patients continue to pose thera-
peutic challenges for the aggressive nature of the disease,
which is prone to relapse, and the lack of appropriate, molec-
ularly targeted agents [10]. Based on the findings presented
herein, it may be possible to envision antagonists of Notch
[49] and of survivin [21] as potential molecular therapy for
basal breast cancer patients. Agents that interfere with Notch
signaling inhibit the enzyme γ-secretase, which is responsible
for the activating intracellular cleavage of Notch upon ligand
binding at the cell surface [15]. Despite concerns of specificity
[50] and potential intestinal toxicity [51], γ-secretase inhibitor
molecules are being tested as molecular therapy for leukemic
patients harboring activating mutations in Notch [49]. In our
recent studies, systemic administration of a peptidyl γ-secre-
tase inhibitor significantly inhibited breast cancer growth in
vivo, and almost completely abolished metastatic dissemina-
tion, with no detectable organ or systemic toxicity [35]. Antag-
onists of survivin are also available in the clinic, producing
encouraging patient responses and manageable toxicity in
early-phase clinical trials [21].
In summary, we have extended recent in vitro observations
[35] and have validated the existence of a functional Notch-1/
survivin signaling axis, in vivo, selectively in patients with basal
breast cancer. Targeting Notch-1 signaling in model breast
cancer cells lowered survivin levels, resulting in pronounced
anti-tumor effects [35]. Taken together with the stringent cor-
relation reported here across disparate tumor series, in vivo,
this observation raises the possibility that basal breast cancer
cells may selectively become dependent on, or addicted to,
Notch/survivin signaling for their maintenance [52]. Although
it is unclear to what extent oncogene addiction maintains the
malignant phenotype in vivo [53], antagonists of such path-
ways have produced impressive clinical responses, at least in
certain patient subsets [54]. A similar rationale may be envi-
sioned here for targeting Notch and survivin in basal breast
cancer patients, especially if this pathway can be disabled in a
progenitor/stem cell compartment, acting as a potential dis-
ease reservoir contributing to a high incidence of relapses.
Conclusion
Expression of Notch-1 and survivin segregates with clinically
aggressive and recurrence-prone basal breast cancer. Antag-
onists of these signaling pathways may be considered as tar-
geted, novel molecular therapy of basal breast cancer.
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